TREAT WITH A KNOWN MOLECULE AND SAFETY PROFILE
The reassurance of treating your patients with the tried-and-trusted aflibercept molecule
In PULSAR, EYLEA® (aflibercept) 8 mg demonstrated a safety profile consistent with EYLEA 2 mg from baseline through Week 96, with no new safety signals reported through Week 156*
*EYLEA 2 mg was dosed at fixed Q8 intervals to Week 48 after 3 initial monthly injections.
PULSAR safety
Adverse events in patients receiving EYLEA 8 mg were consistent with EYLEA 2 mg
PULSAR: Most frequent AEs through Week 48
Adapted from Korobelnik J-F. 2022.
*Any ocular treatment-emergent AE in the study eye.
†Treatment-emergent events.
‡All events.
Intraocular pressure values were consistent across all treatment arms through Week 48
PULSAR: IOP through Week 48
Adapted from Korobelnik J-F. 2022.
Intraocular inflammation values were consistent across all treatment arms through Week 48
PULSAR: IOI through Week 48
Adapted from Korobelnik J-F. 2022.
- There were no cases of endophthalmitis or occlusive retinal vasculitis in PULSAR through Week 48
- Reported IOI terms: chorioretinitis, iridocyclitis, iritis, vitreal cells, vitritis
*Treatment-emergent events.
2Q8, 2 mg every 8 weeks; 8Q12, 8 mg every 12 weeks; 8Q16, 8 mg every 16 weeks; AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; DMO, diabetic macular oedema; eSAF, extension safety analysis set; IOI, intraocular inflammation; IOP, intraocular pressure; MoA, mechanism of action; nAMD, neovascular (wet) age-related macular degeneration; Q8, every 8 weeks; SAE, serious adverse event; SAF, safety analysis set; TEAE, treatment-emergent adverse event.
PP-EYL-GB-2933 | November 2025